Electromed, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Electromed, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	25.9	28.3	31.3	32.5	35.8	41.7	48.1	54.7	64	73.8
Cost of revenue	5.29	6.53	7.45	7.27	8.45	10.2	11.5	13	14	15.8
Gross profit	20.6	21.8	23.8	25.2	27.3	31.4	36.5	41.7	50	57.9
Research and development	0.6	0.25	0.58	1.05	1.72	1.36	0.92	0.66	1	1.31
Selling, general and administrative	16.4	18.8	20.4	19.9	22.4	27.1	31.6	34.5	39.3	42.7
Selling and marketing	0.38	0.47	0.58	0.78	1.06	0.94	1.24	1.49	1.42	1.68
Operating expenses	17	19.1	21	20.1	24.2	28.5	32.5	35.1	40.3	44.1
Operating income	3.57	2.71	2.83	5.12	3.14	2.97	4.01	6.58	9.66	13.9
Interest income	0.02
Pre-tax income	3.52	2.73	2.92	5.24	3.17	3	4.09	7.04	10.3	14.4
Income tax	1.29	0.9	0.94	1.08	0.81	0.69	0.92	1.89	2.75	3.06
Net income	2.23	1.83	1.98	4.16	2.36	2.31	3.17	5.15	7.54	11.3
EBITDA	4.21	3.39	3.63	5.74	3.62	3.48	4.56	7.37	10.7	14.7
EPS, basic	0.26	0.22	0.24	0.50	0.28	0.27	0.37	0.60	0.89	1.37
EPS, diluted	0.25	0.21	0.23	0.47	0.27	0.26	0.36	0.58	0.85	1.30
Shares, basic (weighted)	8.56	8.21	8.31	8.4	8.57	8.47	8.46	8.56	8.45	8.27
Shares, diluted (weighted)	8.86	8.62	8.63	8.83	8.91	8.77	8.7	8.86	8.91	8.69

Balance sheet

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Cash and equivalents	5.57	7.46	7.81	10.5	11.9	8.15	7.37	16.1	15.3	20.5
Receivables	9.95	11.8	12.8	12.9	17	21.1	24.1	23.3	24.7	29.8
Inventory	2.56	2.49	2.62	3.09	2.11	3.18	4.22	3.71	3.3	3.68
Other current assets	0.39	0.76	0.35	0.35	0.28	1.87	1.58	0.33	0.39	1.17
Total current assets	18.5	23.3	24.5	28	31.7	34.5	37.8	44.2	45.1	57.4
Property, plant and equipment	3.3	3.09	3.6	3.79	3.61	4.57	5.67	5.17	4.71	5.21
Lease right-of-use assets			0.05	0.08	0.09	0.12		0.09	0.2	0.13
Intangible assets	0.72	0.65	0.58	0.6	0.66	0.6	0.61	0.66	0.37	0.38
Other non-current assets	0.1	0.05	0.05	0.08	0.09	0.12	0.16	0.09	1.17	1.27
Total assets	23.1	27.4	29.4	33.2	37.1	41.4	45.8	52.2	53.8	66.3
Accounts payable	0.66	0.81	0.59	0.56	0.69	1.26	1.37	1.01	2.67	2.64
Accrued liabilities	0.95	1.27	1.4	1.4	2.47	2.74	3.02	3.89	5.08	6.07
Short-term debt	0.05	0.03	0.03	0.07	0.03
Total current liabilities	2.9	4.8	3.65	2.99	4.64	7.15	8.05	7.68	10.5	12.2
Long-term debt	1.1
Other non-current liabilities			0.01	0.01				0.01	0.13	0.07
Total liabilities	3.99	4.74	3.67	3	4.69	7.19	8.14	7.69	10.6	12.3
Total debt	1.15	0.03	0.03	0.07	0.03
Paid-in capital	14	15	16.1	16.5	17.4	18.3	18.8	20.8	21.9	25.3
Retained earnings	4.96	9.52	9.52	13.7	14.9	15.8	18.8	23.7	21.2	28.6
Shareholders' equity	19.8	22.6	25.7	30.3	32.4	34.2	37.7	44.5	43.2	54
Total equity	19.8	22.6	25.7	30.3	32.4	34.2	37.7	44.5	43.2	54
Total liabilities and equity	23.1	27.4	29.4	33.2	37.1	41.4	45.8	52.2	53.8	66.3
Shares outstanding	8.62	8.29	8.41	8.57	8.53	8.48	8.56	8.64	8.35	8.37

Cash flow statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Net income	2.23	1.83	1.98	4.16	2.36	2.31	3.17	5.15	7.54	11.3
Depreciation and amortization	0.64	0.68	0.8	0.62	0.48	0.5	0.55	0.79	1.04	0.87
Stock-based compensation	0.48	0.86	0.92	0.9	1.02	0.98	0.71	1.69	3.06	2.72
Deferred income tax	-0.12	-0.36	-0.27	-0.13	-0.29	-0.49	-0.04	-0.57	-0.31	0.43
Change in receivables	-2.34	-1.28	-0.95	-0.18	-4.09	-4.02	-3.08	0.8	-1.33	-5.15
Change in inventory	-0.03	0.23	-0.11	-0.45	0.97	-1.07	-1.03	0.46	0.18	-0.52
Change in payables	-0.34	0.54	-0.2	-0.47	0.21	2.17	0.42	-1.21	1.65	0.65
Cash from operations	1.19	2.44	2.59	4.2	3.08	-0.69	1.32	9.07	11.4	9.67
Capital expenditures	-0.62	-0.53	-1.33	-0.84	-0.29	-1.43	-1.65	-0.29	-0.26	-1.25
Cash from investing	-0.69	-0.57	-1.39	-0.98	-0.45	-1.53	-1.72	-0.4	-0.31	-1.3
Stock issued		0.06	0.25	0.08				0.31	0.4	0.97
Share buybacks					-1.12	-1.45	-0.15	-0.28	-10	-3.92
Cash from financing	-0.05	0.01	-0.85	-0.55	-1.22	-1.53	-0.38	0.04	-11.9	-3.2
Net change in cash			0.35	2.67	1.41	-3.74	-0.78	8.71	-0.79	5.16
Free cash flow	0.57	1.92	1.26	3.35	2.79	-2.11	-0.33	8.78	11.1	8.41
Interest paid	0.06	0.05	0.02	0
Income taxes paid	1.09	1.02	1.31	1.76	-0.14	-0.08	-0.31	2.51	3.74	3.39

Key metrics

Worked out from the statements above. Latest values use fiscal 2026. Valuation uses the share price of $27.88 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	78.5%	Gross profit / revenue.
Operating margin	18.8%	Operating income / revenue.
EBITDA margin	20.0%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	19.5%	Pre-tax income / revenue.
Net margin	15.3%	Net income / revenue.
FCF margin	11.4%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	13.1%	Cash from operations / revenue.
Effective tax rate	21.3%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	23.3%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	18.8%	Net income / average total assets.
Return on invested capital (ROIC)	35.6%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	1.8%	Research and development expense / revenue.
SG&A / revenue	57.9%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	3.7%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	1.7%	Capital expenditures / revenue.
D&A / revenue	1.2%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	15.3%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	15.4%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	15.6%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	16.0%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	16.6%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	16.2%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	43.7%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	51.3%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	34.6%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	37.9%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	47.9%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	32.5%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	49.9%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	52.8%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 5y	36.8%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	52.9%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	53.4%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	36.9%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	-15.2%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	94.4%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	25.7%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	-24.4%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 5y	24.7%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	24.9%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	12.7%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	10.7%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	23.2%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	13.1%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	12.3%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-2.5%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-0.0%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-0.5%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	4.69x	Current assets / current liabilities.
Quick ratio	4.11x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	1.67x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	18.5%	Total liabilities / total assets.
Working capital	$45.1M	Current assets - current liabilities.
Goodwill and intangibles / assets	0.6%	(Goodwill + intangible assets) / total assets.
Tangible book value	$53.6M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.23x	Revenue / average total assets.
Fixed asset turnover	14.9x	Revenue / average property, plant and equipment.
Inventory turnover	4.54x	Cost of revenue / average inventory.
Days inventory	80 days	365 x average inventory / cost of revenue.
Receivables turnover	2.71x	Revenue / average receivables.
Days sales outstanding	135 days	365 x average receivables / revenue.
Days payables	61 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	154 days	Days inventory + days sales outstanding - days payables.
FCF conversion	74.4%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	13.0%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$1.30	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic	$1.37	Net income per basic share, as reported (split-adjusted).
Revenue per share	$8.49	Revenue / diluted weighted shares.
FCF per share	$0.97	Free cash flow / diluted weighted shares.
Operating cash flow per share	$1.11	Cash from operations / diluted weighted shares.
Book value per share	$6.45	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$6.41	Tangible book value / shares outstanding.
Cash per share	$2.44	(Cash + short-term investments) / shares outstanding.
Buybacks / FCF	46.6%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$230.8M	Share price x shares outstanding.
Enterprise value	$210.4M	Market cap + total debt - cash - short-term investments.
P/E	20.4x	Market cap / net income. Only when net income is positive.
P/S	3.13x	Market cap / revenue.
P/B	4.28x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	4.31x	Market cap / tangible book value, when positive.
P/FCF	27.4x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	23.9x	Market cap / cash from operations, when positive.
EV/Sales	2.85x	Enterprise value / revenue.
EV/EBIT	15.2x	Enterprise value / operating income, when both are positive.
EV/EBITDA	14.3x	Enterprise value / EBITDA, when both are positive.
EV/FCF	25.0x	Enterprise value / free cash flow, when both are positive.
FCF yield	3.6%	Free cash flow / market cap.
Earnings yield	4.9%	Net income / market cap (the inverse of P/E).
Shareholder yield	1.7%	(Dividends paid + share buybacks) / market cap.
PEG	0.38x	P/E / EPS growth per year over 3 years (in percent). Only when both are positive.

What was Electromed, Inc.'s revenue in fiscal 2026?

Electromed, Inc. reported revenue of $73.8M for fiscal 2026, 15.3% higher than the year before.

Was Electromed, Inc. profitable in fiscal 2026?

Yes. Net income was $11.3M, a net margin of 15.3%.

How much free cash flow did Electromed, Inc. generate in fiscal 2026?

Cash from operations of $9.7M minus capital expenditures of $1.3M left free cash flow of $8.4M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Electromed, Inc.